InvestorsHub Logo

MasterBlastr

11/04/16 7:15 AM

#54 RE: Quintessence #53

NMUS 19M O/S, 5M float, $500,000 non-dilutive financing confirmed. Buy this dip, easy mover, prime acquisition candidate in the $8 Billion industry for the treatment of Glaucoma.